Clearline Capital’s Amneal Pharmaceuticals AMRX Stock Holding History

Clearline Capital’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-31,479	Closed	-$226K	–	53
2019 Q2	$226K	Buy	+31,479	New	+$322K	0.11%	50

Other funds holding AMRX

Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Clearline Capital's AMRX Position: Q3 2019 in Review

Clearline Capital sold out of Amneal Pharmaceuticals (AMRX) in Q3 2019, closing a stake of 31,479 shares — an estimated $226K sold.

Clearline Capital first reported a position in AMRX in Q2 2019 and held it in 1 quarter. The position peaked at $226K in Q2 2019. 121 funds tracked by Wall St. Rank hold AMRX as of Q3 2019.

Clearline Capital reported no remaining Amneal Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Clearline Capital sold 31,479 Amneal Pharmaceuticals shares in Q3 2019, an estimated $226K.
Clearline Capital first reported a position in Amneal Pharmaceuticals in Q2 2019 and held it in 1 quarter.
Clearline Capital's Amneal Pharmaceuticals position peaked at $226K in Q2 2019.
121 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2019.

Based on Clearline Capital's 13F filing for Q3 2019, filed 14 Nov 2019.